Behind Casgevy’s First Regional Signal of Cure, the Long Road for Gene-Editing Therapy Into Clinical Practice
A 23-year-old sickle cell patient in Louisiana was described as functionally cured after receiving Casgevy, but the real novelty lies not only in efficacy, but in whether complex cell therapies can be reliably taken up by more regional hospitals.